IL-32,Cys-C和β2-MG在多发性骨髓瘤患者外周血中的表达  

Expression of IL-32,Cys-C andβ2-MG in Peripheral Blood of Multiple Myeloma Patients

作　　者：费晓莉[1] 章帆[2] 张开基 何东[1] 林娟[1] 侯铮 FEI Xiao-li;ZHANG Fan;ZHANG Kai-ji;HE Dong;LIN Juan;HOU Zheng(Department of Hematology,Chengdu First People's Hospital,Chengdu 610016,China;Clinical Laboratory,Chengdu First People's Hospital,Chengdu 610016,China)

机构地区：[1]成都市第一人民医院血液内科,成都610016 [2]成都市第一人民医院检验科,成都610016

出　　处：《西南大学学报（自然科学版）》2021年第3期30-35,共6页Journal of Southwest University(Natural Science Edition)

基　　金：四川省科技厅科研课题(2020YJ0438);成都市卫计委立项课题(2016034).

摘　　要：目的:探讨多发性骨髓瘤(multiple myeloma,MM)患者血清白介素32(interleukin 32,IL-32)、胱抑素-C(Cys-C)和β2微球蛋白(β2-MG)水平变化与MM肿瘤负荷、疾病分期、近期疗效的关系.方法:选择初诊MM患者62例(MM组)和28例健康体检者(对照组),MM组化疗前后、对照组体检当日采集空腹血,采用ELISA法检测IL-32水平,免疫比浊法测定Cys-C,β2-MG水平.结果:MM组患者化疗前血清IL-32,Cys-C,β2-MG水平均显著高于对照组(p<0.05).不同国际分期系统(ISS)分期MM患者化疗前IL-32,Cys-C,β2-MG水平存在显著差异(p<0.05),Ⅲ期MM患者IL-32,Cys-C,β2-MG水平均明显高于Ⅰ期和Ⅱ期患者(p<0.05).化疗前MM患者血清IL-32,Cys-C,β2-MG水平显著高于化疗后(p<0.05).化疗后评估疗效,部分缓解、疾病进展MM患者血清IL-32,Cys-C,β2-MG水平均高于完全缓解MM患者(p<0.05).将血清IL-32,Cys-C,β2-MG水平与MM患者疾病分期、化疗后疗效进行Spearman相关性分析,提示MM患者ISS分期与血清IL-32,Cys-C,β2-MG水平呈正相关(p<0.05),MM患者化疗后疗效与血清IL-32,Cys-C,β2-MG水平呈负相关(p<0.05).结论:IL-32可能在MM发生、发展中发挥作用;血清IL-32,Cys-C,β2-MG水平变化与MM患者肿瘤负荷、疾病分期及近期疗效相关.上述指标检测简单快速易操作,可以为临床诊疗工作提供有利的实验依据.Objective:To understand the relationship of the changes in serum interleukin-32(IL-32),cystatin C(Cys-C)andβ2-micro-globulin(β2-MG)levels in multiple myeloma(MM)patients with the tumor load,disease stage and clinical efficacy of MM.Methods:Sixty-two MM patients(MM group)and 28 healthy subjects(control group)were selected.Fasting blood was collected before and after chemotherapy in the MM group and on the day of physical examination in the control group.The levels of IL-32 were detected by ELISA,and the levels of Cys-C andβ2-MG were determined by immunoturbidimetry.Results:Serum levels of IL-32,Cys-C andβ2-MG in the MM group before chemotherapy were significantly higher than those in thecontrol group(p<0.05).There were significant differences in IL-32,Cys-C andβ2-MG levels in MM patients of different ISS stages(p<0.05):MM patients of stageⅢhad significantly higherIL-32,Cys-C andβ2-MG levels than patients of stages I and II(p<0.05).Serum levels of IL-32,Cys-Candβ2-MG in MM patients before chemotherapy were significantly higher than those after chemotherapy(p<0.05).After chemotherapy,itseficacy was evaluated.The serum levels of IL-32,Cys-C andβ2-MG in MM patients with partial remission and disease progression were all higher than those in MM patients with complete remission(p<0.05).Spearman correlation analysis indicated thatISS stage of MM patients at initial diagnosis was positively correlated with theirserum levels of IL-32,Cys-C andβ2-MG(p<0.05),while the efficacy after chemotherapy was negatively correlated with theirserum levels of IL-32,Cys-C andβ2-MG(p<0.05).Conclusions:IL-32 may play a role in the development of MM.Changes in serum IL-32,Cys-C andβ2-MG levels are correlated with tumor load,disease stage and short-term efficacy of MM patients.Detection of the above-mentioned indexes is simple,rapid and easy to operate,and is recommended for appication in clinical diagnosis and treatment.

关 键 词：多发性骨髓瘤 白介素32 胱抑素-C Β2-微球蛋白 

分 类 号：R733.3[医药卫生—肿瘤]